Effects of kisspeptin on diabetic rat platelets

Zsófia Mezei, Sándor Váczi, Viktória Török, Csaba Stumpf, Rita Ónody, I. Földesi, Gyula Szabó

Research output: Contribution to journalArticle

Abstract

Hyperglycemia, hyperlipidemia, and free radicals result in platelet activation and atherogenesis. Kisspeptin (KP) is able to regulate metabolism, hemostasis, and the development of atherosclerosis. We examined whether platelet aggregation of streptozotocin-induced diabetic rats depends on the inducer type and if KP-13 and RF-9 (a kisspeptin receptor modifier) can influence platelet function. We measured the speed and the maximum of aggregation, along with the area under the curve. Serum glucose and calcium levels and urine formation of diabetic animals increased, while the body mass and platelet count decreased. Collagen was the most effective inducer of platelet aggregation. The aggregability of nondiabetic platelets was elevated in the presence of 5 × 10−8 mol/L KP-13. This effect was less expressed in diabetic animals. The effectivity of RF-9 was stronger than that of KP-13 in nondiabetic platelets, however it was ineffective in diabetic animals. RF-9 pre-treatment did not change the effects of 5 × 10−8 mol/L KP-13 in either animal group. The in vivo activation of diabetic platelets, which may be due to elevated serum calcium, induces thrombocytopenia and may lead to reduced in vitro aggregability. We could not demonstrate the antagonistic effect of RF-9 against KP-13 in isolated platelets.

Original languageEnglish
Pages (from-to)1319-1326
Number of pages8
JournalCanadian Journal of Physiology and Pharmacology
Volume95
Issue number11
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Kisspeptins
Blood Platelets
Platelet Activation
Platelet Aggregation
Atherosclerosis
Calcium
Streptozocin
Hyperlipidemias
Hemostasis
Serum
Platelet Count
Hyperglycemia
Thrombocytopenia
Area Under Curve
Free Radicals
Collagen
Urine
Glucose

Keywords

  • Aggregation
  • Aggregometry
  • Diabetes
  • Kisspeptin
  • Platelets
  • RF-9
  • Streptozotocin

ASJC Scopus subject areas

  • Physiology
  • Pharmacology
  • Physiology (medical)

Cite this

Mezei, Z., Váczi, S., Török, V., Stumpf, C., Ónody, R., Földesi, I., & Szabó, G. (2017). Effects of kisspeptin on diabetic rat platelets. Canadian Journal of Physiology and Pharmacology, 95(11), 1319-1326. https://doi.org/10.1139/cjpp-2017-0036

Effects of kisspeptin on diabetic rat platelets. / Mezei, Zsófia; Váczi, Sándor; Török, Viktória; Stumpf, Csaba; Ónody, Rita; Földesi, I.; Szabó, Gyula.

In: Canadian Journal of Physiology and Pharmacology, Vol. 95, No. 11, 01.01.2017, p. 1319-1326.

Research output: Contribution to journalArticle

Mezei, Z, Váczi, S, Török, V, Stumpf, C, Ónody, R, Földesi, I & Szabó, G 2017, 'Effects of kisspeptin on diabetic rat platelets', Canadian Journal of Physiology and Pharmacology, vol. 95, no. 11, pp. 1319-1326. https://doi.org/10.1139/cjpp-2017-0036
Mezei, Zsófia ; Váczi, Sándor ; Török, Viktória ; Stumpf, Csaba ; Ónody, Rita ; Földesi, I. ; Szabó, Gyula. / Effects of kisspeptin on diabetic rat platelets. In: Canadian Journal of Physiology and Pharmacology. 2017 ; Vol. 95, No. 11. pp. 1319-1326.
@article{92d99554c6064fb995c9be2f4b887657,
title = "Effects of kisspeptin on diabetic rat platelets",
abstract = "Hyperglycemia, hyperlipidemia, and free radicals result in platelet activation and atherogenesis. Kisspeptin (KP) is able to regulate metabolism, hemostasis, and the development of atherosclerosis. We examined whether platelet aggregation of streptozotocin-induced diabetic rats depends on the inducer type and if KP-13 and RF-9 (a kisspeptin receptor modifier) can influence platelet function. We measured the speed and the maximum of aggregation, along with the area under the curve. Serum glucose and calcium levels and urine formation of diabetic animals increased, while the body mass and platelet count decreased. Collagen was the most effective inducer of platelet aggregation. The aggregability of nondiabetic platelets was elevated in the presence of 5 × 10−8 mol/L KP-13. This effect was less expressed in diabetic animals. The effectivity of RF-9 was stronger than that of KP-13 in nondiabetic platelets, however it was ineffective in diabetic animals. RF-9 pre-treatment did not change the effects of 5 × 10−8 mol/L KP-13 in either animal group. The in vivo activation of diabetic platelets, which may be due to elevated serum calcium, induces thrombocytopenia and may lead to reduced in vitro aggregability. We could not demonstrate the antagonistic effect of RF-9 against KP-13 in isolated platelets.",
keywords = "Aggregation, Aggregometry, Diabetes, Kisspeptin, Platelets, RF-9, Streptozotocin",
author = "Zs{\'o}fia Mezei and S{\'a}ndor V{\'a}czi and Vikt{\'o}ria T{\"o}r{\"o}k and Csaba Stumpf and Rita {\'O}nody and I. F{\"o}ldesi and Gyula Szab{\'o}",
year = "2017",
month = "1",
day = "1",
doi = "10.1139/cjpp-2017-0036",
language = "English",
volume = "95",
pages = "1319--1326",
journal = "Canadian Journal of Physiology and Pharmacology",
issn = "0008-4212",
publisher = "National Research Council of Canada",
number = "11",

}

TY - JOUR

T1 - Effects of kisspeptin on diabetic rat platelets

AU - Mezei, Zsófia

AU - Váczi, Sándor

AU - Török, Viktória

AU - Stumpf, Csaba

AU - Ónody, Rita

AU - Földesi, I.

AU - Szabó, Gyula

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Hyperglycemia, hyperlipidemia, and free radicals result in platelet activation and atherogenesis. Kisspeptin (KP) is able to regulate metabolism, hemostasis, and the development of atherosclerosis. We examined whether platelet aggregation of streptozotocin-induced diabetic rats depends on the inducer type and if KP-13 and RF-9 (a kisspeptin receptor modifier) can influence platelet function. We measured the speed and the maximum of aggregation, along with the area under the curve. Serum glucose and calcium levels and urine formation of diabetic animals increased, while the body mass and platelet count decreased. Collagen was the most effective inducer of platelet aggregation. The aggregability of nondiabetic platelets was elevated in the presence of 5 × 10−8 mol/L KP-13. This effect was less expressed in diabetic animals. The effectivity of RF-9 was stronger than that of KP-13 in nondiabetic platelets, however it was ineffective in diabetic animals. RF-9 pre-treatment did not change the effects of 5 × 10−8 mol/L KP-13 in either animal group. The in vivo activation of diabetic platelets, which may be due to elevated serum calcium, induces thrombocytopenia and may lead to reduced in vitro aggregability. We could not demonstrate the antagonistic effect of RF-9 against KP-13 in isolated platelets.

AB - Hyperglycemia, hyperlipidemia, and free radicals result in platelet activation and atherogenesis. Kisspeptin (KP) is able to regulate metabolism, hemostasis, and the development of atherosclerosis. We examined whether platelet aggregation of streptozotocin-induced diabetic rats depends on the inducer type and if KP-13 and RF-9 (a kisspeptin receptor modifier) can influence platelet function. We measured the speed and the maximum of aggregation, along with the area under the curve. Serum glucose and calcium levels and urine formation of diabetic animals increased, while the body mass and platelet count decreased. Collagen was the most effective inducer of platelet aggregation. The aggregability of nondiabetic platelets was elevated in the presence of 5 × 10−8 mol/L KP-13. This effect was less expressed in diabetic animals. The effectivity of RF-9 was stronger than that of KP-13 in nondiabetic platelets, however it was ineffective in diabetic animals. RF-9 pre-treatment did not change the effects of 5 × 10−8 mol/L KP-13 in either animal group. The in vivo activation of diabetic platelets, which may be due to elevated serum calcium, induces thrombocytopenia and may lead to reduced in vitro aggregability. We could not demonstrate the antagonistic effect of RF-9 against KP-13 in isolated platelets.

KW - Aggregation

KW - Aggregometry

KW - Diabetes

KW - Kisspeptin

KW - Platelets

KW - RF-9

KW - Streptozotocin

UR - http://www.scopus.com/inward/record.url?scp=85032445401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032445401&partnerID=8YFLogxK

U2 - 10.1139/cjpp-2017-0036

DO - 10.1139/cjpp-2017-0036

M3 - Article

VL - 95

SP - 1319

EP - 1326

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

SN - 0008-4212

IS - 11

ER -